Insider Trading Alert - FANG, MOH And PG Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 3, 2014, 139 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,308.00 to $197,500,000.00.

Highlighted Stocks Traded by Insiders:

Diamondback Energy (FANG) - FREE Research Report

Wexford Capital Lp who is 10% Owner at Diamondback Energy sold 114,608 shares at $64.64 on March 3, 2014. Following this transaction, the 10% Owner owned 10.5 million shares meaning that the stake was reduced by 1.08% with the 114,608-share transaction.

The shares most recently traded at $65.24, up $0.60, or 0.93% since the insider transaction. Historical insider transactions for Diamondback Energy go as follows:

  • 4-Week # shares sold: 705,009
  • 12-Week # shares sold: 3.0 million
  • 24-Week # shares sold: 3.3 million

The average volume for Diamondback Energy has been 898,100 shares per day over the past 30 days. Diamondback Energy has a market cap of $3.0 billion and is part of the basic materials sector and energy industry. Shares are up 21.8% year-to-date as of the close of trading on Monday.

Diamondback Energy, Inc., an independent oil and natural gas company, focuses on the acquisition, development, exploration, and exploitation of onshore oil and natural gas reserves in the Permian Basin in West Texas. The company has a P/E ratio of 49.9. Currently there are 13 analysts that rate Diamondback Energy a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FANG - FREE

TheStreet Quant Ratings rates Diamondback Energy as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Diamondback Energy Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Molina Healthcare (MOH) - FREE Research Report

Cooperman Daniel who is Director at Molina Healthcare sold 1,500 shares at $37.41 on March 3, 2014. Following this transaction, the Director owned 9,700 shares meaning that the stake was reduced by 13.39% with the 1,500-share transaction.

Carruthers Garrey who is Director at Molina Healthcare sold 3,460 shares at $37.34 on March 3, 2014. Following this transaction, the Director owned 16,122 shares meaning that the stake was reduced by 17.67% with the 3,460-share transaction.

The shares most recently traded at $37.93, up $0.59, or 1.56% since the insider transaction. Historical insider transactions for Molina Healthcare go as follows:

  • 4-Week # shares sold: 33,047
  • 12-Week # shares sold: 36,750
  • 24-Week # shares sold: 36,750

The average volume for Molina Healthcare has been 590,900 shares per day over the past 30 days. Molina Healthcare has a market cap of $1.7 billion and is part of the health care sector and health services industry. Shares are up 7.65% year-to-date as of the close of trading on Monday.

Molina Healthcare, Inc. provides Medicaid-related solutions to meet the health care needs of low-income families and individuals, as well as to assist state agencies in their administration of the Medicaid program. The company has a P/E ratio of 39.2. Currently there are 3 analysts that rate Molina Healthcare a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MOH - FREE

TheStreet Quant Ratings rates Molina Healthcare as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Molina Healthcare Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Procter & Gamble (PG) - FREE Research Report

Geissler Werner who is Vice Chairman - GO at Procter & Gamble sold 10,874 shares at $77.70 on March 3, 2014. Following this transaction, the Vice Chairman - GO owned 220,364 shares meaning that the stake was reduced by 4.7% with the 10,874-share transaction.

Pritchard Marc S. who is Global Brand Building Officer at Procter & Gamble sold 4,561 shares at $77.70 on March 3, 2014. Following this transaction, the Global Brand Building Officer owned 104,404 shares meaning that the stake was reduced by 4.19% with the 4,561-share transaction.

The shares most recently traded at $78.49, up $0.79, or 1.01% since the insider transaction. Historical insider transactions for Procter & Gamble go as follows:

  • 4-Week # shares sold: 1,860
  • 12-Week # shares sold: 1,860
  • 24-Week # shares sold: 3,825

The average volume for Procter & Gamble has been 9.3 million shares per day over the past 30 days. Procter & Gamble has a market cap of $213.3 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are down 4.83% year-to-date as of the close of trading on Monday.

The Procter & Gamble Company, together with its subsidiaries, manufactures and sells branded consumer packaged goods. The company operates through five segments: Beauty, Grooming, Health Care, Fabric Care and Home Care, and Baby Care and Family Care. The stock currently has a dividend yield of 3.06%. The company has a P/E ratio of 21.1. Currently there are 9 analysts that rate Procter & Gamble a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PG - FREE

TheStreet Quant Ratings rates Procter & Gamble as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Procter & Gamble Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists